参芎葡萄糖注射液在心力衰竭患者中使用安全性及有效性的Meta分析

Meta-analysis of the safty and efficacy of Shenqiong Glucose Injection on patients with heart failure

目的评价基于基础抗心力衰竭(心衰)治疗下参芎葡萄糖在心力衰竭患者中使用安全性及有效性。方法系统地搜索CNKI、万方、维普和Cochrane图书馆的相关随机对照试验。根据异质性,将研究按照随机效应或固定效应模型合并,评估用药物后心功能、左室射血分数、脑钠肽(BNP)等观察指标,同时评价其药物不良反应情况。结果11项研究符合纳入标准。固定效应模型的汇总结果表明,在改善心功能上所有治疗后在有效性方面具有可比性(肺心病心衰组:RR=0.34,95%CI:0.22~0.53,P=0.79;冠心病心衰组:RR=0.33,95%CI:0.17~0.63,P=0.80)。随机效应模型进行Meta分析表明,BNP明显下降,左室射血分数明显改善(MD=10.24,95%CI:8.64~11.84,P=0.74)。结论基础抗心衰治疗联合参芎葡萄糖可进一步改善慢性心力衰竭患者心功能、左室射血分数,降低BNP,使用安全有效。

Objective To evaluate the safety and efficacy of Shenqiong Glusose Injection on the patients with heart failure on the basis of basic therapy.Methods The databases were searched systematically included CNKI,Wanfang Data,VIP,and Cochrane Library about the correlative randomized controlled trials(RCTs).The research was affiliated with the random-effect or fixed-effect model according to the heterogeneity,aiming to assess the heart function,left ventricular sinister ejection fraction(LVEF),BNP and drug adverse reaction after taking drugs.Results 11 studies were internalized into the research.The analysis and summary of fixed-effect model indicated that it has comparability on the efficacy of heart function improving about all the study(pulmonary heart disease-heart failure group:RR=0.34,95% CI:0.22~0.53,P=0.79;coronary heart disease-heart failure group:RR=0.33,95% CI:0.17~0.63,P=0.80).Meta-analysis combined with random effect model indicated that BNP has been decreased(MD=-70.43,95% CI:-80.35^-60.50,P=0.0003),and the LVEF has been improved(MD=10.24,95% CI:8.64~11.84,P=0.74).Conclusion Shenqiong Glucose Injection combined with the basic therapy could improved the heart function,BNP and LVEF on the patients of heart failure,which was safe meanwhile.